Sandoz Revenue and Competitors
Estimated Revenue & Valuation
- Sandoz's estimated annual revenue is currently $4B per year.
- Sandoz's estimated revenue per employee is $201,000
Employee Data
- Sandoz has 20005 Employees.
- Sandoz grew their employee count by 9% last year.
Sandoz's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Global Process Owner - Learning Partner | Reveal Email/Phone |
2 | Global Senior Solution Owner, Service Management, DevOps & Productivity Platform | Reveal Email/Phone |
3 | CFO Czech Republic | Reveal Email/Phone |
4 | CFO Lek d.d. | Reveal Email/Phone |
5 | CFO Global B2B Sandoz | Reveal Email/Phone |
6 | CFO | Reveal Email/Phone |
7 | CFO Central America & Caribbean | Reveal Email/Phone |
8 | Business Planning Analysis Manager Gulf and Levant & Interim CFO | Reveal Email/Phone |
9 | Chief Accounting Officer | Reveal Email/Phone |
10 | CFO Europe | Reveal Email/Phone |
Sandoz Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $16.1M | 80 | 1% | N/A | N/A |
#2 | $1392.3M | 0 | N/A | N/A | N/A |
#3 | N/A | 16258 | -2% | $30M | N/A |
What Is Sandoz?
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of approximately 1000 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and Eon Labs (US). In 2008, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.6 billion.
keywords:N/A
N/A
Total Funding
20005
Number of Employees
$4B
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sandoz News
Sandoz is a leading provider of ophthalmic medicines in the US, with over 36 product families for the treatment of a wide range of eye diseases.
Basel: Sandoz has announced the US launch of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution...
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR).
Dimethyl Fumarate DR Capsules is indicated as monotherapy for the treatment of relapsing remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of disability. PrSandoz® Dimethyl Fumarate Delayed-Release Capsules is an important generic pr ...
PRINCETON, N.J., July 16, 2021 /PRNewswire/ -- Sandoz, a global leader in generic and biosimilar medicines, today announced the immediate US availability of generic Ferumoxytol, an intravenous medicine used to treat iron deficiency anemia (IDA). Ferumoxytol, a generic equivalent to AMAG Pharm ...
Other Companies in Princeton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $203410M | 30254 | 8% | N/A |